Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Missing Link in Dinitrogen Fixation Enabled by Hydrazido Isomerization.

Journal of the American Chemical Society·2026
Same author

A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention.

ACS central science·2026
Same author

Investigation of zirconium interactions with a DOTA based theranostic hybrid nanoparticle using X-ray absorption spectroscopy.

Physical chemistry chemical physics : PCCP·2026
Same author

Core competencies in prostate HDR brachytherapy: An American Brachytherapy Society Endorsed Competency Framework.

Brachytherapy·2026
Same author

Optimizing mouse models for mRNA vaccines: addressing dose translation challenges.

Scientific reports·2026
Same author

EDNRB-dependent endothelin signaling reduces proliferation and promotes proneural-to-mesenchymal transition in gliomas.

Molecular oncology·2026

Related Experiment Video

Updated: Feb 19, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K

Imaging PD-L1 Expression with ImmunoPET.

Charles Truillet1,2, Hsueh Ling J Oh3, Siok Ping Yeo3

  • 1Department of Radiology and Biomedical Imaging, ‡Department of Medicine, §Helen Diller Family Comprehensive Cancer Center, ∥Department of Pharmaceutical Chemistry, and ⊥Department of Radiation Oncology, University of California, San Francisco , 505 Parnassus Avenue, San Francisco, California 94143, United States.

Bioconjugate Chemistry
|November 11, 2017
PubMed
Summary
This summary is machine-generated.

A new immunoPET tracer, 89Zr-C4, detects low levels of programmed death-ligand 1 (PD-L1) in cancer models. This highly sensitive tool could improve patient selection for cancer immunotherapy.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Related Experiment Videos

Last Updated: Feb 19, 2026

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.1K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Area of Science:

  • Oncology
  • Immunology
  • Radiochemistry
  • Medical Imaging

Background:

  • Cancer immunotherapy efficacy relies on target antigen expression.
  • Accurate assessment of target expression is crucial for patient stratification.
  • Existing imaging tools may lack the sensitivity to detect low antigen levels.

Purpose of the Study:

  • To develop a highly sensitive immunoPET tracer for imaging programmed death-ligand 1 (PD-L1).
  • To evaluate the tracer's ability to detect PD-L1 in various preclinical cancer models.
  • To assess the tracer's utility in monitoring treatment-induced changes in PD-L1 expression.

Main Methods:

  • Development of a novel recombinant human IgG1 antibody (C4) targeting human and mouse PD-L1.
  • Radiolabeling of the antibody with zirconium-89 (89Zr).
  • Small animal PET/CT imaging studies in patient-derived xenografts (PDX) and human cancer models.

Main Results:

  • 89Zr-C4 detected PD-L1 in a non-small-cell lung cancer (NSCLC) PDX model with low antigen levels, undetectable by other tracers.
  • The tracer specifically imaged PD-L1 in human NSCLC and prostate cancer models.
  • 89Zr-C4 monitored changes in mouse PD-L1 expression and acute changes due to chemotherapy.

Conclusions:

  • 89Zr-C4 is a highly sensitive immunoPET tracer for imaging low levels of PD-L1.
  • This novel tracer has potential for improved patient selection in cancer immunotherapy.
  • 89Zr-C4 can visualize dynamic changes in PD-L1 expression in response to therapy.